Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone for fatigue in pediatric and young adult Long COVID
NCT07916259Phase 3Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
naltrexone
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT07916259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07916259.